A “wet chemistry” approach for isolation of 211At from an irradiated bismuth target is described. The approach involves five steps: (1) dissolution of bismuth target in conc. HNO 3; (2) removal of the HNO 3 by distillation; (3) dissolution of residue in 8 M HCl; (4) extraction of 211At from 8 M HCl into DIPE; and (5) extraction of 211At from DIPE into NaOH. Results from 55 “optimized” 211At isolation runs gave recovery yields of approximately 78% after decay and attenuation corrections. An attenuation-corrected average of 26 ± 3 mCi in the target provided isolated (actual) yields of 16 ± 3 mCi of 211At. A sixth step, used for purification of 211At from trace metals, was evaluated in seven runs. In those runs, isolated 211At was distilled under reductive conditions to provide an average 71 ± 8% recovery. RadioHPLC analyses of the isolated 211At solutions, both initial and after distillation, were obtained to examine the 211At species present. The primary species of 211At present was astatide, but astatate and unidentified species were also observed. Studies to determine the effect of bismuth attenuation on 211At were conducted to estimate an attenuation factor (~1.33) for adjustment of 211At readings in the bismuth target.
References
[1]
Wilbur, D.S. [211At]astatine-labeled compound stability: Issues with released [211At]astatide and development of labeling reagents to increase stability. Curr. Radiopharm. 2008, 1, 144–176, doi:10.2174/1874471010801030144.
[2]
Lucignani, G. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1729–1733, doi:10.1007/s00259-008-0856-4.
Andersson, H.; Cederkrantz, E.; Back, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2—A phase I study. J. Nucl. Med. 2009, 50, 1153–1160, doi:10.2967/jnumed.109.062604.
[6]
Andersson, H.; Elgqvist, J.; Horvath, G.; Hultborn, R.; Jacobsson, L.; Jensen, H.; Karlsson, B.; Lindegren, S.; Palm, S. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: An overview of results in an ovarian tumor model. Clin. Cancer Res. 2003, 9, 3914S–3921S.
[7]
Palm, S.; Back, T.; Claesson, I.; Danielsson, A.; Elgqvist, J.; Frost, S.; Hultborn, R.; Jensen, H.; Lindegren, S.; Jacobsson, L. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 572–579, doi:10.1016/j.ijrobp.2007.06.023.
[8]
Sundberg, A.L.; Almqvist, Y.; Tolmachev, V.; Carlsson, J. Treatment of cultured glioma cells with the EGFR-TKI gefitinib (\“Iressa\”, ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. Eur. J. Nucl. Med. Mol. Imag. 2003, 30, 727–729, doi:10.1007/s00259-003-1129-x.
[9]
Petrich, T.; Korkmaz, Z.; Krull, D.; Fromke, C.; Meyer, G.J.; Knapp, W.H. In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 851–861, doi:10.1007/s00259-009-1356-x.
[10]
Zhang, M.; Yao, Z.; Zhang, Z.; Garmestani, K.; Talanov, V.S.; Plascjak, P.S.; Yu, S.; Kim, H.S.; Goldman, C.K.; Paik, C.H.; Brechbiel, M.W.; Carrasquillo, J.A.; Waldmann, T.A. The Anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res. 2006, 66, 8227–8232, doi:10.1158/0008-5472.CAN-06-1189.
[11]
Aurlien, E.; Larsen, R.H.; Kvalheim, G.; Bruland, O.S. Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin’s lymphoma cells. Br. J. Cancer 2000, 83, 1375–1379, doi:10.1054/bjoc.2000.1453.
[12]
Persson, M.I.; Gedda, L.; Jensen, H.J.; Lundqvist, H.; Malmstrom, P.U.; Tolmachev, V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol. Rep. 2006, 15, 673–680.
[13]
Robinson, M.K.; Shaller, C.; Garmestani, K.; Plascjak, P.S.; Hodge, K.M.; Yuan, Q.A.; Marks, J.D.; Waldmann, T.A.; Brechbiel, M.W.; Adams, G.P. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res. 2008, 14, 875–882, doi:10.1158/1078-0432.CCR-07-1250.
[14]
Boskovitz, A.; McLendon, R.E.; Okamura, T.; Sampson, J.H.; Bigner, D.D.; Zalutsky, M.R. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab. Nucl. Med. Biol. 2009, 36, 659–669, doi:10.1016/j.nucmedbio.2009.04.003.
[15]
Nestor, M.; Persson, M.; van Dongen, G.A.; Jensen, H.J.; Lundqvist, H.; Anniko, M.; Tolmachev, V. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 1296–1304, doi:10.1007/s00259-005-1848-2.
[16]
Cheng, J.; Ekberg, T.; Engstrom, M.; Nestor, M.; Jensen, H.J.; Tolmachev, V.; Anniko, M. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. The Laryngoscope 2007, 117, 1013–1018, doi:10.1097/MLG.0b013e31804b1a6d.
[17]
Willhauck, M.J.; Samani, B.R.; Wolf, I.; Senekowitsch-Schmidtke, R.; Stark, H.J.; Meyer, G.J.; Knapp, W.H.; Goke, B.; Morris, J.C.; Spitzweg, C. The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1272–1281, doi:10.1007/s00259-008-0775-4.
[18]
Hall, E.J. LET and RBE. In Radiobiology for the Radiologist, 3rd ed. ed.; J. B. Lippincott Company: Philadelphia, PA, USA, 1988; pp. 161–178.
[19]
Hall, E.J. Radiation Damage and Dose Rate Effect. In Radiobiology for the Radiologist, 3rd ed. ed.; J. B. Lippincott Company: Philadelphia, PA, USA, 1988; pp. 107–136.
[20]
Hall, E.J. The Oxygen Effect and Reoxygenation. In Radiobiology for the Radiologist, 3rd ed. ed.; J. B. Lippincott Company: Philadelphia, PA, USA, 1988; pp. 137–160.
[21]
Cancer Facts and Figures; American Cancer Society: Atlanta, GA, USA, 2013.
[22]
Zalutsky, M.R.; Pruszynski, M. Astatine-211: Production and availability. Curr. Radiopharm. 2011, 4, 177–185, doi:10.2174/1874471011104030177.
[23]
Eberle, S.H. Chemical Behavior and Compounds of Astatine. In Gmelin Handbook of Chemistry, Astatine; Kugler, H.K., Keller, C., Eds.; Springer-Verlag: Berlin, Germany, 1985; pp. 183–259.
[24]
Meyer, G.-J.; R？ssler, K. Preparation of inorganic forms and interhalogen compounds of 211At via distillation techniques. Radiochem. Radioanal. Lett. 1976, 25, 377–390.
[25]
Lambrecht, R.M.; Mirzadeh, S. Cyclotron Isotopes and Radiopharmaceuticals-XXXV. Astatine-211. Int. J. Appl. Radiat. Isot. 1985, 36, 443–450, doi:10.1016/0020-708X(85)90207-8.
[26]
Lindegren, S.; Back, T.; Jensen, H.J. Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields. Appl. Radiat. Isot. 2001, 55, 157–160, doi:10.1016/S0969-8043(01)00044-6.
[27]
Wilbur, D.S.; Hadley, S.W.; Hines, J.J.; Atcher, R.W. Assessment of Dry Distillation Methods for Improving Protein Labeling Yields with Astatine-211. J. Labelled Compd. Radiopharm. 1990, 30, 214–215.
[28]
Wilbur, D.S.; Vessella, R.L.; Stray, J.E.; Goffe, D.K.; Blouke, K.A.; Atcher, R.W. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. Nucl. Med. Biol. 1993, 20, 917–927, doi:10.1016/0969-8051(93)90092-9.
[29]
Gagnon, K.; Risler, R.; Pal, S.; Hamlin, D.; Orzechowski, J.; Pavan, R.; Zeisler, S.; Wilbur, D.S. Design and evaluation of an external high-current target for production of 211At. J. Labelled Compd. Radiopharm. 2012, 55, 436–440, doi:10.1002/jlcr.2968.
[30]
Neumann, H.M. Solvent distribution studies of the chemistry of astatine. J. Inorg. Nucl. Chem. 1957, 4, 349–353, doi:10.1016/0022-1902(57)80018-9.
[31]
Neirinckx, R.D.; Smit, J.A. Separation of astatine-211 from bismuth metal. Anal. Chem. Acta 1973, 63, 201–204, doi:10.1016/S0003-2670(01)82189-9.
[32]
Yordanov, A.T.; Pozzi, O.; Carlin, S.; Akabani, G.; Wieland, B.; Zalutsky, M. Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications. J. Radioanal. Nucl. Chem. 2004, 262, 593–599, doi:10.1007/s10967-004-0481-z.
[33]
Zona, C.; Bonardi, M.L.; Groppi, F.; Morzenti, S.; Canella, L.; Persico, E.; Menapace, E.; Alfassi, Z.B.; Abbas, K.; Holzwarth, U.; Gibson, N. Wet-chemistry method for the separation of no-carrier-added 211At/211gPo from 209Bi target irradiated by alpha-beam cyclotron. J. Radioanal. Nucl. Chem. 2008, 276, 819–824, doi:10.1007/s10967-008-0638-2.
[34]
Sajonz, P.; Bookalam, J.; Miller, R.A. Separation of periodate, iodate and iodide on a C-18 stationary phase. Dependence of the retention on the temperature and solvent composition. monitoring of an oxidative clevage reaction. Chromatographia 2006, 64, 635–640, doi:10.1365/s10337-006-0082-9.
[35]
Alliot, C.; Cherel, M.; Barbet, J.; Sauvage, T.; Montavon, G. Extraction of astatine-211 in diisopropylether (DIPE). Radiochim. Acta 2009, 97, 161–165.
[36]
Ruth, T.J.; Dombsky, M.; D’Auria, J.M.; Ward, T.E. Radiochemistry of Astatine; U.S. Department of Energy (DOE): Springfield, VA, USA, 1988.
[37]
Johnson, G.L.; Leininger, R.F.; Segre, E. Chemical properties of astatine. I. J. Chem. Phys. 1949, 17, 1–10, doi:10.1063/1.1747034.
[38]
Norseyev, Y.V.; Khalkin, V.A. Discovery and study of new inorganic and organic astatine compounds. Radiochemistry 1999, 41, 318–321.
[39]
Champion, J.; Alliot, C.; Renault, E.; Mokili, B.M.; Cherel, M.; Galland, N.; Montavon, G. Astatine standard redox potentials and speciation in acidic medium. J. Phys. Chem. A 2010, 114, 576–582, doi:10.1021/jp9077008.
[40]
R？ssler, K.; Tornau, W.; St？cklin, G. Rapid separation of carrier-free inorganic and organic compounds of radioiodine and astatine by high-pressure liquid chromatography. J. Radioanal. Chem. 1974, 21, 199–209, doi:10.1007/BF02520862.
[41]
Sabatié-Gogova, A.; Champion, J.; Huclier, S.; Michel, N.; Pottier, F.; Galland, N.; Asfari, Z.; Chérel, M.; Montavon, G. Characterization of At？species in simple and biological media by high performance anion exchange chromatography coupled to gamma detector. Anal. Chim. Acta 2012, 721, 182–188, doi:10.1016/j.aca.2012.01.052.
[42]
Champion, J.; Sabatie-Gogova, A.; Bassal, F.; Ayed, T.; Alliot, C.; Galland, N.; Montavon, G. Investigation of astatine(III) hydrolyzed species: Experiments and relativistic calculations. J. Phys. Chem. A 2013, 117, 1983–1990, doi:10.1021/jp3099413.
[43]
Larsen, R.H.; Wieland, B.W.; Zalutsky, M.R. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211At reaction. Appl. Radiat. Isot. 1996, 47, 135–143, doi:10.1016/0969-8043(95)00285-5.
[44]
Lebeda, O.; Jiran, R.; Ralis, J.; Stursa, J. A new internal target system for production of 211At on the cyclotron U-120M. Appl. Radiat. Isot. 2005, 63, 49–53, doi:10.1016/j.apradiso.2005.02.006.
[45]
Schwarz, U.P.; Plascjak, P.; Beitzel, M.P.; Gansow, O.A.; Eckelman, W.C.; Waldmann, T.A. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl. Med. Biol. 1998, 25, 89–93, doi:10.1016/S0969-8051(97)00165-0.
[46]
Bourgeois, M.; Guerard, F.; Alliot, C.; Mougin-Degraef, M.; Rajerison, H.; Remaud-Le Saec, P.; Gestin, J.-F.; Davodeau, F.; Cherel, M.; Barbet, J.; Faivre-Chauvet, A. Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction. J. Labelled Compd. Radiopharm. 2008, 51, 379–383, doi:10.1002/jlcr.1543.
[47]
Wilbur, D.S. Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. Curr. Radiopharm. 2011, 4, 214–247, doi:10.2174/1874471011104030214.
Berry, F.J.; Collins, R.D.; Parish, R.V.; Moore, L.S. Studies of iodine in nitric acid and of iodine adsorbed onto silver-impregnated silica. Inorg. Chim. Acta 1987, 126, 119–124, doi:10.1016/S0020-1693(00)81251-7.
[50]
Norseyev, Y.V.; Khalkin, V.A. The stability constants of chloride complexes of mono-valent astatine in nitric acid solution. J. Inorg. Nucl. Chem. 1968, 30, 3239–3243, doi:10.1016/0022-1902(68)80118-6.
